Dasatinib and quercetin form a research programme spread across academic trials. There is no single development code or uniform clinical indication. The evidence must be read study by study.
The earliest experiments identified different susceptibilities among senescent cell types. Human researchers then examined whether the combination changed tissue markers and disease measures. This dossier follows that translation, including results that did not meet their primary endpoint.
A new randomised MASH study published on 1 October 2026 adds a disease-specific result. Its 31 participants cannot settle the broader question of whether senolytics extend human healthspan.
- Test survival pathwaysActivity differs across the cell types studied.
- Measure affected tissueBiopsies can answer local mechanistic questions.
- Observe disease outcomesClinical effects need their own comparison and follow-up.
A marker measured in one tissue cannot supply a clinical outcome in another organ. Sources for this account.
The mechanism
Senescent cells stop dividing and can persist in tissue. Some secrete inflammatory and tissue-remodelling factors. The 2015 discovery study examined survival networks that allowed these cells to resist apoptosis, then tested drugs that interfered with the networks.
Dasatinib and quercetin showed different patterns of activity across the cell types studied. The combination follows from that experimental observation. It should not be assumed that every senescent cell in every tissue has the same drug susceptibility.
The mechanistic chain has several steps: a drug reaches the tissue, affects relevant cells, changes tissue function and eventually changes a disease outcome. A marker measured in a skin or fat biopsy informs one part of that chain. It cannot substitute for a measured clinical outcome in another organ.
Human evidence
In 2019, a nine-person, open-label diabetic kidney disease pilot reported reductions in several senescence-associated markers in fat and skin. It used before-and-after biopsies without a randomised comparator. The finding supported further human investigation; the design could not determine long-term disease benefit.
A 2024 randomised study of 60 postmenopausal women followed bone metabolism for 20 weeks. It did not reduce its primary bone-resorption marker compared with control. Early changes in a bone-formation marker and exploratory subgroup findings generated further questions.
The October 2026 Amsterdam UMC-led MASH trial compared the combination with placebo for 21 weeks. Fibrosis improvement without worsening MASH occurred in 8 of 17 treated participants and 1 of 14 placebo participants. Adverse events were more frequent in the treatment group. Replication, durability and the balance of benefit and harm require larger studies.
Studies and experimental evidence
Diabetic kidney disease pilot
- Design
- Open-label Phase 1, before-and-after
- Population or model
- People with diabetic kidney disease
- Sample size
- 9
- Comparison
- No randomised control
- Duration
- Biopsies before and 11 days after the experimental course
- Outcome
- Senescence-associated tissue markers and circulating factors
Several fat and skin markers decreased
Small uncontrolled pilot; disease benefit and durability unresolved
Funding and interests: NIH and foundations reported
Bone metabolism trial
- Design
- Randomised, open-label Phase 2
- Population or model
- Postmenopausal women selected for elevated T-cell p16 expression
- Sample size
- 60
- Comparison
- Control group
- Duration
- 20 weeks
- Outcome
- Primary: serum CTx change
Primary outcome did not differ; early secondary and exploratory findings reported
Surrogate endpoint; small subgroups; no fracture outcome
Funding and interests: See full paper disclosures
Fibrotic MASH trial
- Design
- Single-centre, double-blind randomised proof-of-principle
- Population or model
- Adults with biopsy-proven fibrotic MASH
- Sample size
- 31 randomised; 27 completed
- Comparison
- Placebo
- Duration
- 21 weeks
- Outcome
- At least one stage fibrosis improvement without MASH worsening
8/17 versus 1/14 achieved primary outcome
Small sample, baseline imbalance, limited duration; more adverse events on intervention
Funding and interests: ZONMW and additional academic grants; senolytic patent interests disclosed
Development history
Drug discovery paper published
Cell and animal experiments established the combination's research rationale.
Human tissue pilot published
Researchers reported changes in senescence-associated markers.
Bone primary endpoint missed
The randomised trial added a negative primary result.
MASH proof-of-principle result published
A small placebo-controlled trial reported a liver histology result.
Unresolved questions
- Which tissue measurements can reliably identify a responsive senescent-cell burden?
- Can the MASH histological result be replicated in larger, independent studies?
- How long do any tissue or disease changes persist after an experimental course?
- Which observed effects depend on senescent-cell removal, given the drugs' other biological actions?
- Do disease-specific benefits translate into improvements in several functional domains?
The MASH authors call for further trials. The sources listed here do not establish a date for a larger replication study. Its protocol would need to preserve a clear population, comparison and endpoint so the result can be interpreted alongside the earlier experiments.
Sources
- Paper · 22 Apr 2015The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Discovery experiments in cells and animals.
Checked 4 Oct 2026 - Paper · 18 Sept 2019Senolytics decrease senescent cells in humans
Nine-person diabetic kidney disease pilot.
Checked 4 Oct 2026 - Paper · 2 Jul 2024Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women
Randomised bone metabolism study; full text also available at PMC11705617.
Checked 4 Oct 2026 - Paper · 1 Oct 2026Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis
New small randomised liver study; includes funding and conflicts.
Checked 4 Oct 2026
Dr T Smith, organic chemist and science educator. Review date: 4 Oct 2026. Report a correction.